Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 213790, 9 pages
http://dx.doi.org/10.1155/2014/213790
Research Article

Polymorphism of XRCC1, XRCC3, and XPD Genes and Risk of Chronic Myeloid Leukemia

1Department of Medical Genetics, University of Medicine and Pharmacy Tirgu Mures, 38 Gh, Marinescu Street, Romania
2Department of Medical Genetics, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
3Hematology Clinic 1, University of Medicine and Pharmacy Tirgu Mures, Romania
4Hematology Clinic 2, University of Medicine and Pharmacy Tirgu Mures, Romania
5Department of Hematology, “Ion Chiricuta” Cancer Institute, Cluj-Napoca, Romania
6Pediatric Clinic, University of Medicine and Pharmacy Tirgu Mures, Romania
7Laboratory Medicine, University of Medicine and Pharmacy Tirgu Mures, Romania

Received 28 February 2014; Revised 22 April 2014; Accepted 28 April 2014; Published 15 May 2014

Academic Editor: Paul W. Doetsch

Copyright © 2014 Claudia Bănescu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The genetic polymorphisms of X-ray repair cross complementing group 1 (XRCC1), X-ray repair cross complementing group 3 (XRCC3), and xeroderma pigmentosum complementation group D (XPD) repair genes may lead to genetic instability and leukemogenesis. The purpose of the study was to evaluate the association between XRCC1 Arg399Gln, Arg280His and Arg194Trp, XRCC3 Thr241Met, and XPD Lys751Gln polymorphisms and the risk of developing CML in Romanian patients. A total of 156 patients diagnosed with CML and 180 healthy controls were included in this study. We found no association between CML and XRCC1 or XRCC3 variant genotypes in any of the investigated cases. A significant difference was observed in the variant genotype frequencies of the XPD Lys751Gln polymorphism between the patients with CML and control group (for variant homozygous genotypes, ; 95% –4.67; P value = 0.016 and for combined heterozygous and variant homozygous genotypes, ; 95% –2.69; P value = 0.019). This was also observed when analyzing the variant 751Gln allele ( ; 95% –2.11; P value = 0.008). Our results suggest that the XPD Lys751Gln variant genotype increases the risk of CML.